Loading
Precision Biosciences Inc Stock: price and insider trades · United States
3 insiders bought €26k of shares over the last 90 days, the latest by Frankel Stanley, filed 30 Sept 2026.
Cluster: 3 buyers in 30 daysPrecision Biosciences Inc: what insiders have been doing
Headquartered in Durham, United States, Precision Biosciences Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 20 filings were filed, from 8 insiders.
Open-market activity splits into 6 purchases totalling €55k and 1 sale totalling €19k; 3 insiders sit on the buying side and 1 insider on the selling side. Taken together, the purchases exceed the sales by €35k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 3 senior executives. Amoroso Michael filed the largest sale, €19k, on 4 November 2025.
In all, 6 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 30 September 2026, which is 18 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 20 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 22 purchases and 7 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 34.3 m USD and net income at -45.7 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
119
Thresholds
n/a
Buy Volume
€378,577
22 ops. · all time
Sell Volume
€314,959
7 ops. · all time
Who traded when
BuySaleMelinda Brown6 buys
Geno J. Germano4 buys
John Alexander Kelly2 buys1 sale
Kevin Buehler3 buys
Michael Amoroso3 sales
Stanley Frankel3 buys
Since the insiders bought
- +55.5%Entry US$4.52 · Close at T+90 US$7.03
- +55.5%Entry US$4.52 · Close at T+90 US$7.03
- +55.5%Entry US$4.52 · Close at T+90 US$7.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.03
Analyst consensus
5 analysts1.00/5
US$18.00Target US$29.40(+388%)US$60.00
Income statement
RevenueUS$34.3M
EBITDA-US$42.4M-124% margin
Net income-US$45.7M-117.0% margin
Valuation
PER (forward)-3.2x
P/Book3.5x
Beta1.28
Balance sheet & cash
Market capUS$166.4M
Total debtUS$28.8M
Free Cash Flow-US$66.5M
Debt / Equity62%
Profitability & ownership
ROE-135.1%
ROA-19.4%
% insiders8.0%
% institutions68.7%
Last declaration on 30 September 2026
Declarations119 total
1,000 shares@ US$6.000.0035% mcap19.1% of flowCommon StockSEC:0001628280-26-063980:0
Canonical exit: 27 Dec 2026 (T+90)
1,135 shares@ US$6.270.0033% mcap13.8% of flowCommon StockSEC:0001628280-26-063767:0
Canonical exit: 24 Dec 2026 (T+90)
2,609 shares@ US$6.280.0076% mcap24.9% of flowCommon StockSEC:0001628280-26-063766:0
Canonical exit: 24 Dec 2026 (T+90)
21,000 sharesCommon StockSEC:0001628280-26-037536:0
21,000 sharesCommon StockSEC:0001628280-26-037539:0
67,797 shares0Common StockSEC:0001628280-26-009804:0
16,667 shares0Common StockSEC:0001628280-26-009802:0
16,667 shares0Common StockSEC:0001628280-26-009801:0
27,584 shares0Common StockSEC:0001628280-26-009803:0
1,978 shares0Common StockSEC:0001628280-26-003148:0
3,888 sharesCommon StockSEC:0001628280-26-003147:0
2,500 sharesCommon StockSEC:0001628280-26-003146:0
8,888 sharesCommon StockSEC:0001628280-26-003149:0
3,000 shares@ US$4.7227.7% of flowCommon StockSEC:0001628280-25-057485:0
Canonical exit: 16 Mar 2026 (T+90)
2,700 shares@ US$4.7048.4% of flowCommon StockSEC:0001628280-25-057483:0
Canonical exit: 16 Mar 2026 (T+90)
1,381 shares@ US$4.9715.0% of flowCommon StockSEC:0001628280-25-057482:0
Canonical exit: 15 Mar 2026 (T+90)
3,605 shares0Common StockSEC:0001628280-25-048858:0
1,835 shares0Common StockSEC:0001628280-25-048856:0
9,444 shares0Common StockSEC:0001628280-25-048855:0
3,409 shares@ US$6.499.6% of flowCommon StockSEC:0001628280-25-048855:1
2,700 shares@ US$4.9751.6% of flowCommon StockSEC:0001628280-25-043156:0
Canonical exit: 25 Dec 2025 (T+90)
1,400 shares@ US$4.8914.9% of flowCommon StockSEC:0001628280-25-042524:0
Canonical exit: 21 Dec 2025 (T+90)
14,827 shares@ US$4.2613.2% of flowCommon StockSEC:0001628280-25-034531:0
1,682 shares@ US$4.1415.3% of flowCommon StockSEC:0001628280-25-033200:0
Canonical exit: 23 Sept 2025 (T+90)
5,076 shares@ US$4.1631.2% of flowCommon StockSEC:0001628280-25-033199:0
Canonical exit: 23 Sept 2025 (T+90)
25 of 119 declarations
About Precision Biosciences Inc
Precision BioSciences, Inc. (ticker DTIL) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. Headquartered in Durham, North Carolina, the company was incorporated in 2006 and built around its proprietary ARCUS® genome-editing platform, which originated from research led by its founders at Duke University. For investors, this is a classic clinical-stage biotech profile: heavy R&D spending, limited near-term commercial revenue visibility, and valuation driven primarily by clinical data, partnerships, and access to capital.
Precision’s core business today is the development of in vivo gene-editing therapies for genetic and infectious diseases with significant unmet medical need. The company describes ARCUS as a compact, simple genome-editing technology with capabilities across gene cutting, insertion, and excision. While Precision historically pursued programs in immuno-oncology and allogeneic CAR-T, its recent strategic emphasis has shifted toward in vivo editing, which the company views as the most differentiated and scalable long-term opportunity. This shift is important for investors because it concentrates the narrative around a smaller number of higher-impact programs.
Read moreShow less
The platform and pipeline are central to the investment case. Current attention has focused on programs in hepatitis B and selected rare genetic diseases, alongside preclinical work designed to validate ARCUS as a precise editing tool with a potentially favorable specificity profile. Precision has also highlighted scientific publications and early-stage data intended to demonstrate the breadth of ARCUS applications, including gene insertion and other complex edits. In addition, the company has pursued partnerships and licensing relationships with pharmaceutical collaborators, helping to spread development risk while preserving upside from future milestones, royalties, or program-specific economics.
From a competitive standpoint, Precision operates in a crowded and fast-moving genome-editing landscape alongside larger, better-capitalized players and multiple next-generation editing platforms. Its potential edge lies in ARCUS’ small size, modularity, and the company’s focus on sophisticated edits that may be harder to achieve with some competing systems. That said, Precision remains a small-cap biotechnology company, and its outlook depends heavily on execution in clinical development, regulatory milestones, and financing conditions. As with many gene-editing names, the path to durable commercial value is still contingent on human data and eventual therapeutic adoption.
Geographically, the company is concentrated in the United States, with operations centered in Durham, North Carolina. Recent corporate activity has included ongoing pipeline updates, new scientific disclosures, and capital-markets transactions to support development. For international investors, DTIL is best understood as a high-risk, high-upside biotech platform story on NASDAQ in the United States, where the key questions remain clinical translation, partner traction, and balance-sheet resilience.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
